Home » New Data on Hydroxychloroquine Shows Little Benefit
New Data on Hydroxychloroquine Shows Little Benefit
New clinical trial data from China suggest that hydroxychloroquine may not be a useful treatment for COVID-19 patients.
The study of 150 hospitalized COVID-19 patients found that adding the antimalarial drug did not improve upon the standard-of-care.
The malaria drug did appear to reduce inflammation, but more adverse events were observed in the hydroxychloroquine group vs. the standard-of-care cohort.
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May